Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Marcello Giunta,1 Eino Solje,2 Fabrizio Gardoni,3 Barbara Borroni,1 Alberto Benussi1 1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 2Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland; 3Department of P...
Main Authors: | Giunta M, Solje E, Gardoni F, Borroni B, Benussi A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-03-01
|
Series: | Journal of Experimental Pharmacology |
Subjects: | |
Online Access: | https://www.dovepress.com/experimental-disease-modifying-agents-for-frontotemporal-lobar-degener-peer-reviewed-fulltext-article-JEP |
Similar Items
-
Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration
by: Ahmed Yousef, et al.
Published: (2017-09-01) -
Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration
by: Qin Chen, et al.
Published: (2020-02-01) -
Therapeutic and diagnostic challenges for frontotemporal dementia
by: Simon eD'Alton, et al.
Published: (2014-08-01) -
Neuropathology of frontotemporal lobar degeneration: A review
by: Valéria Santoro Bahia, et al. -
Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion
by: Anna Junttila, et al.
Published: (2016-04-01)